Boston Scientific Corporation BSX
Set alert
As of Nov 2, 12:22 PM ET
- YTD
- -53.87%
- 1 year
- -56.33%
- Open
- 42.07
- Prev close
- 41.98
- Mkt cap
- 63.75B
- Vol
- 8.72M
- Avg vol
- 19.60M
- EPS
- 2.37
- P/E
- 18.56
- Div yield
- 0.00%
More statistics
- Low
- 41.90
- High
- 44.21
- Forward P/E
- 13.16
- Beta
- 0.57
- Short ratio
- 2.17
- Inst. own
- 94.93%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 3, 2027
- 50-d avg
- 44.94
- 200-d avg
- 56.78
- 1y target
- 51.53
5Y chart
Events in this range
- Oct 22, 2025Earnings: 0.75; estimate 0.714; surprise 5.04%
- Feb 4, 2026Earnings: 0.8; estimate 0.781; surprise 2.43%
- Apr 22, 2026Earnings: 0.8; estimate 0.788; surprise 1.52%
- Jul 29, 2026Earnings: 0.86; estimate 0.835; surprise 2.99%
- Oct 28, 2026Earnings: 0.73; estimate 0.727; surprise 0.41%
- Oct 29, 2026Rating: RBC Capital · Outperform → Outperform
- Oct 29, 2026Rating: Bernstein · Outperform → Outperform
- Oct 29, 2026Rating: Canaccord Genuity · Buy → Buy
- Oct 29, 2026Downgrade: Jefferies · Buy → Hold
- Oct 30, 2026Rating: Barclays · Equal-Weight → Equal-Weight
- Oct 30, 2026Downgrade: TD Cowen · Buy → Hold
Signals (94)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 2026 | 12 hours ago |
| SMA: Bearish | Oct 26, 2026 | 1 week ago |
| SMA: Bullish | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| SMA: Bullish | Jul 27, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 13, 2026 | 3 months ago |
| RSI: Oversold | May 25, 2026 | 5 months ago |
| RSI: Oversold | Mar 2, 2026 | 8 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Jan 5, 2026 | 10 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| SMA: Bearish | Nov 17, 2025 | 11 months ago |
| SMA: Bearish | Nov 17, 2025 | 11 months ago |
| SMA: Bullish | Nov 10, 2025 | 11 months ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| SMA: Bearish | Sep 15, 2025 | 1 year ago |
| SMA: Bearish | Sep 8, 2025 | 1 year ago |
| SMA: Bullish | Aug 18, 2025 | 1 year ago |
| SMA: Bearish | Aug 4, 2025 | 1 year ago |
| SMA: Bullish | Jul 21, 2025 | 1 year ago |
| SMA: Bearish | Jul 7, 2025 | 1 year ago |
| SMA: Bullish | Jun 23, 2025 | 1 year ago |
| SMA: Bearish | Jun 9, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 2, 2025 | 1 year ago |
| MACD: Buy Signal | May 26, 2025 | 1 year ago |
| SMA: Bullish | Apr 21, 2025 | 1 year ago |
| SMA: Bullish | Apr 7, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 10, 2025 | 1 year ago |
| SMA: Bearish | Mar 3, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 6, 2025 | 1 year ago |
| RSI: Overbought | Jan 6, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 16, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 18, 2024 | 1 year ago |
| RSI: Overbought | Nov 18, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 11, 2024 | 1 year ago |
| SMA: Bullish | Nov 4, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 4, 2024 | 1 year ago |
| RSI: Overbought | Nov 4, 2024 | 1 year ago |
| SMA: Bearish | Oct 28, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 28, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 9, 2024 | 2 years ago |
| SMA: Bullish | Aug 12, 2024 | 2 years ago |
| RSI: Overbought | Aug 12, 2024 | 2 years ago |
| SMA: Bearish | Jul 22, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 1, 2024 | 2 years ago |
| SMA: Bullish | Apr 22, 2024 | 2 years ago |
| SMA: Bearish | Apr 15, 2024 | 2 years ago |
| RSI: Overbought | Jan 8, 2024 | 2 years ago |
| MACD: Buy Signal | Nov 20, 2023 | 2 years ago |
| SMA: Bullish | Nov 13, 2023 | 2 years ago |
| SMA: Bullish | Nov 13, 2023 | 2 years ago |
| SMA: Bearish | Nov 6, 2023 | 2 years ago |
| SMA: Bearish | Nov 6, 2023 | 2 years ago |
| SMA: Bullish | Oct 30, 2023 | 3 years ago |
| SMA: Bullish | Oct 30, 2023 | 3 years ago |
| SMA: Bearish | Oct 9, 2023 | 3 years ago |
| SMA: Bearish | Oct 2, 2023 | 3 years ago |
| SMA: Bullish | Aug 28, 2023 | 3 years ago |
| SMA: Bearish | Aug 14, 2023 | 3 years ago |
| SMA: Bearish | Jul 24, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| SMA: Bearish | Jul 3, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 3, 2023 | 3 years ago |
| SMA: Bullish | Jun 12, 2023 | 3 years ago |
| MACD: Buy Signal | Jun 12, 2023 | 3 years ago |
| SMA: Bearish | Jun 5, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 5, 2023 | 3 years ago |
| SMA: Bullish | May 29, 2023 | 3 years ago |
| SMA: Bearish | May 22, 2023 | 3 years ago |
| RSI: Overbought | May 8, 2023 | 3 years ago |
| RSI: Overbought | Apr 10, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 20, 2023 | 3 years ago |
| SMA: Bullish | Mar 13, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 6, 2023 | 3 years ago |
| SMA: Bullish | Jan 30, 2023 | 3 years ago |
| SMA: Bearish | Jan 16, 2023 | 3 years ago |
| SMA: Bullish | Oct 17, 2022 | 4 years ago |
| SMA: Bullish | Oct 17, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 17, 2022 | 4 years ago |
| MACD: Sell Signal | Oct 3, 2022 | 4 years ago |
| SMA: Bearish | Sep 19, 2022 | 4 years ago |
| SMA: Bearish | Sep 19, 2022 | 4 years ago |
| SMA: Bullish | Sep 5, 2022 | 4 years ago |
| SMA: Bearish | Aug 22, 2022 | 4 years ago |
| SMA: Bullish | Aug 8, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 1, 2022 | 4 years ago |
| SMA: Bullish | Jul 25, 2022 | 4 years ago |
| SMA: Bullish | Mar 14, 2022 | 4 years ago |
| SMA: Bearish | Mar 7, 2022 | 4 years ago |
| SMA: Bullish | Feb 21, 2022 | 4 years ago |
| SMA: Bearish | Feb 14, 2022 | 4 years ago |
Key statistics
- Market cap
- 60.78B
- Enterprise value
- 74.17B
- Trailing P/E
- 17.70
- Forward P/E
- 13.16
- PEG ratio
- 0.60
- Price / sales
- 2.88
- Price / book
- 2.43
- EPS (TTM)
- 2.37
- Beta
- 0.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 16.62%
- Revenue (TTM)
- 21.07B
- Revenue growth
- 1.40%
- Free cash flow
- 0
- Total cash
- 539.00M
- Total debt
- 12.62B
- Return on equity
- 14.32%
- Shares outstanding
- 1.45B
- Short % of float
- 2.81%
- 50-day average
- 44.94
- 200-day average
- 56.78
Analyst view
Consensus: buy
- Target (low)
- 41.00
- Target (mean)
- 51.53
- Target (high)
- 78.00
- Strong buy6
- Buy14
- Hold11
- Sell0
- Strong sell0
Next earnings
Feb 3, 2027
Expected Feb 3, 2027. Consensus EPS estimate 0.7756.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2027 | Dec 30, 2026 | 0.79 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | 0.727 | 0.73 | 0.00 | +0.41% |
| Jul 29, 2026 | Jun 30, 2026 | 0.835 | 0.86 | +0.03 | +2.99% |
| Apr 22, 2026 | Mar 31, 2026 | 0.788 | 0.80 | +0.01 | +1.52% |
| Feb 4, 2026 | Dec 31, 2025 | 0.781 | 0.80 | +0.02 | +2.43% |
| Oct 22, 2025 | Sep 30, 2025 | 0.714 | 0.75 | +0.04 | +5.04% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | TD Cowen | down | Buy | Hold |
| Oct 30, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Oct 29, 2026 | Jefferies | down | Buy | Hold |
| Oct 29, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 29, 2026 | Bernstein | main | Outperform | Outperform |
| Oct 29, 2026 | RBC Capital | main | Outperform | Outperform |
About Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bostonscientific.com
News
- Intuitive Surgical vs. Boston Scientific: Which Stock Is a Better Buy Now?
- TD Cowen Downgrades Boston Scientific to Hold, Lowers Price Target to $46
- Barclays Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $45
- Buy, Sell, or Hold? Today's Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte.
- New Strong Sell Stocks for October 30th
- Jefferies Downgrades Boston Scientific to Hold, Lowers Price Target to $46
- Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $48
- Penumbra, Inc. Reports Third Quarter 2026 Financial Results
- RBC Capital Maintains Outperform on Boston Scientific, Lowers Price Target to $52
- Citigroup Maintains Neutral on Boston Scientific, Lowers Price Target to $44
Your note
Sign in to keep a note on BSX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRENNAN DANIEL J | Chief Financial Officer | Sale | Feb 18, 2025 | 225,808 |
| BROWN VANCE R | General Counsel | Stock Award(Grant) | Feb 12, 2026 | 54,244 |
| BUTCHER ARTHUR C | Officer | Conversion of Exercise of derivative security | Apr 30, 2026 | 77,115 |
| CARRUTHERS WENDY | Officer | Sale | Dec 1, 2024 | 29,308 |
| FITZGERALD JOSEPH MICHAEL | Officer | Stock Award(Grant) | Feb 12, 2026 | 219,141 |
| LUDWIG EDWARD J. | Director | Purchase | Jul 30, 2026 | 30,359 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.95% | 129,680,916 | 5.44B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.70% | 97,087,553 | 4.07B | Jun 29, 2026 |
| State Street Corporation | 4.84% | 70,111,196 | 2.94B | Jun 29, 2026 |
| Primecap Management Company | 3.49% | 50,520,914 | 2.12B | Jun 29, 2026 |
| FMR, LLC | 3.15% | 45,702,845 | 1.92B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.31% | 33,440,102 | 1.40B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.26% | 47,181,284 | 1.98B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.66% | 38,518,788 | 1.62B | Jun 29, 2026 |
| VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund | 2.13% | 30,831,039 | 1.29B | Jun 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.33% | 19,294,226 | 809.20M | Aug 30, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 19,310,588 | 809.89M | Sep 29, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.23% | 17,894,864 | 750.51M | Sep 29, 2026 |